TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced that a poster featuring its lead therapeutic candidate, TTX-MC138, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on Oct. 23 in Madrid, Spain. The presentation will highlight the latest clinical update from the Phase 1a trial evaluating TTX-MC138 in patients with advanced solid tumors.
TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression. The company’s focus on this biomarker is central to its approach, as miR-10b is a well-documented indicator of metastasis. By targeting miR-10b, TransCode aims to address a critical unmet need in oncology: treating metastatic tumors that overexpress this microRNA. The upcoming ESMO presentation will provide the latest clinical data from the Phase 1a trial, which is evaluating the safety and preliminary activity of TTX-MC138 in patients with advanced solid tumors.
The importance of this announcement lies in its potential to advance the treatment landscape for high-risk cancers. Metastatic disease remains the leading cause of cancer-related mortality, and therapies that specifically target metastatic mechanisms are urgently needed. TTX-MC138 represents a novel approach by inhibiting miR-10b, which could potentially slow or halt metastatic progression. Investors and industry observers will be watching the ESMO data closely for signs of clinical benefit and safety, as positive results could significantly enhance the company’s profile and attract partnership or funding opportunities.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. In addition to TTX-MC138, the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For more details, the full press release is available at https://nnw.fm/sGqsS, and the latest news and updates relating to RNAZ can be found in the company’s newsroom at https://nnw.fm/RNAZ.
The announcement was distributed through NetworkNewsWire (NNW), a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NNW is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, as well as article and editorial syndication to 5,000+ outlets and enhanced press release enhancement to ensure maximum impact. These services help companies like TransCode gain visibility among investors and the public.
For readers, the ESMO presentation could offer critical insights into the future of RNA-based cancer therapies. If TTX-MC138 demonstrates promising safety and efficacy, it could pave the way for larger trials and eventual regulatory approval, potentially transforming treatment paradigms for metastatic cancers. However, as with any clinical-stage program, the data will be scrutinized for any signals of toxicity or lack of efficacy. The outcome will be pivotal for TransCode’s trajectory and could influence investment decisions in the broader RNA therapeutics space.
